Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced its quarterly earnings data on Monday. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12, Zacks reports.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL traded up $0.04 during trading hours on Monday, hitting $1.32. The stock had a trading volume of 358,061 shares, compared to its average volume of 1,101,745. The stock has a market capitalization of $95.22 million, a price-to-earnings ratio of -0.58 and a beta of 1.87. The company’s fifty day moving average is $1.56 and its two-hundred day moving average is $1.45. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $4.44.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Qube Research & Technologies Ltd bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Corient Private Wealth LLC acquired a new position in Zentalis Pharmaceuticals in the second quarter worth $83,000. State of Wyoming grew its holdings in shares of Zentalis Pharmaceuticals by 63.4% during the second quarter. State of Wyoming now owns 73,797 shares of the company’s stock worth $86,000 after purchasing an additional 28,621 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Zentalis Pharmaceuticals by 622.8% in the second quarter. Ameriprise Financial Inc. now owns 91,195 shares of the company’s stock valued at $106,000 after buying an additional 78,578 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of Zentalis Pharmaceuticals by 373.1% in the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock valued at $194,000 after buying an additional 131,780 shares in the last quarter.

Analyst Ratings Changes

ZNTL has been the subject of a number of recent research reports. Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. Finally, HC Wainwright raised shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.84.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.